SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBaronsmead Vt Regulatory News (BVT)

Share Price Information for Baronsmead Vt (BVT)

Share Price is delayed by 15 minutes
Get Live Data
45.00    0.00 (0.00%)
Bid:
44.00
Ask:
46.00
Spread: 2.00 (4.545%)
Market Cap: £203.60m
BVT Live PriceLast checked at - London Stock Exchange

Intraday Baronsmead Vt Share Chart

Directorate Change

1 Apr 2025 07:00

RNS Number : 0200D
Baronsmead Venture Trust PLC
01 April 2025
 

1 April 2025

Baronsmead Venture Trust plc

("BVT" or the "Company")

 

Directorate Change

BVT is pleased to announce that Mr David Melvin and Mr Mandeep Singh join the BVT Board as Non-Executive Directors on 1 April 2025.

 

Fiona Miller Smith, Chair of BVT, said: "On behalf of the Board, I am delighted to welcome David and Mandeep to the Board. They each bring a combination of skills and expertise that are highly complementary to the Board."

 

David is an investment and financial services professional with over 30 years of experience in investment banking and private equity.

 

David is the President of HBA Media Limited, a sports media rights business; a senior adviser at Bixteth Partners Limited, a boutique advisory firm; a Principal at 24 Haymarket Private Capital and a member of the Investment Committee of Gonville and Caius College, Cambridge. David previously served as a Non-Executive Director and Chairman of the Audit Committee of Pantheon International Plc, he was also senior adviser at CITIC CLSA Securities, a CITIC Securities Company, and a Partner at TDR Capital, a European private equity firm. Prior to that, he spent 24 years at Merrill Lynch. David is a qualified Chartered Accountant.

 

On his appointment to BVT, David will chair the Audit Committee and will become a member of the Management Engagement and Remuneration Committee and the Nomination Committee.

Mandeep is an experienced founder, CEO, Non-Executive Director, and investor with expertise, and a proven track record, in scaling tech businesses.

Mandeep started his career as a strategy consultant at OC&C and an investor with a Private Equity fund, BC Partners. Between 2013 and 2020, Mandeep was the Founder CEO of Trouva, a SaaS-enabled marketplace. Since, Mandeep served on the Board of Thrift+, an early-stage fashion marketplace and on the global Board of Amnesty International.  He has been an active angel investor in AI businesses including Kaedim, Convergence AI, and TitanML. He is currently a Venture Partner at Hoxton Ventures and an EIR at Founders at the University of Cambridge.

On his appointment to BVT, Mandeep will become a member of all BVT Board Committees.

 

 

There are no other details to be disclosed under 6.4.8R of the Listing Rules.

 

For further information, please contact:

 

Baronsmead VCT Investor Relations

020 7382 0999

baronsmeadvcts@greshamhouse.com

 

LEI: 213800VQ1PQHOJXDDQ88

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOABIGDXUGXDGUB
Date   Source Headline
4th Jun 20263:15 pmRNSNet Asset Value(s)
3rd Jun 202610:15 amRNSNewsletter for the period June 2025 to March 2026
1st Jun 202611:28 amRNSTotal Voting Rights
18th May 20263:45 pmRNSAdmission of Further Securities to Trading
14th May 20262:33 pmRNSDirector/PDMR Shareholding
14th May 20262:15 pmRNSAllotment of Shares and Closure of Offer
11th May 20267:00 amRNSNet Asset Value(s)
5th May 20263:15 pmRNSNet Asset Value(s)
1st May 202611:42 amRNSTotal Voting Rights
8th Apr 202610:15 amRNSAdmission of Further Securities to Trading
1st Apr 202611:48 amRNSTotal Voting Rights
31st Mar 20265:38 pmRNSTransaction in Own Shares
24th Mar 20262:20 pmRNSReplacement - Extension to Application Deadline
24th Mar 202612:20 pmRNSApplication Deadline Extension - Fourth Allotment
20th Mar 20267:00 amRNSResult of AGM
5th Mar 20263:30 pmRNSNet Asset Value(s)
2nd Mar 202611:37 amRNSTotal Voting Rights
26th Feb 202612:15 pmRNSAdmission of Further Securities to Trading
20th Feb 202611:02 amRNSDirector/PDMR Shareholding
19th Feb 20264:31 pmRNSAllotment of Shares and Total Voting Rights
16th Feb 20265:15 pmRNSTransaction in Own Shares
10th Feb 20267:00 amRNSOver-Allotment Facility and Offer Update
5th Feb 20264:15 pmRNSNet Asset Value(s)
2nd Feb 20264:45 pmRNSNet Asset Value(s)
2nd Feb 202610:41 amRNSTotal Voting Rights
29th Jan 20263:35 pmRNSAdmission of Further Securities to Trading
22nd Jan 20263:40 pmRNSAllotment of Shares and Total Voting Rights
12th Jan 202611:35 amRNSPublication of a Supplementary Prospectus
23rd Dec 20257:00 amRNSAnnual Financial Report
23rd Dec 20257:00 amRNSAnnual Financial Report
11th Dec 20257:00 amRNSOffer Update:Close of Early Subscription Incentive
4th Dec 20253:45 pmRNSNet Asset Value(s)
1st Dec 202510:45 amRNSTotal Voting Rights
20th Nov 20251:28 pmRNSDirector/PDMR Shareholding
20th Nov 202512:00 pmRNSAllotment of Shares and Total Voting Rights
6th Nov 20254:00 pmRNSNet Asset Value(s)
29th Oct 20259:45 amRNSNet Asset Value(s)
13th Oct 20252:00 pmRNSPublication of a Prospectus/Offer for Subscription
1st Oct 20257:00 amRNSTotal Voting Rights
29th Sep 20255:53 pmRNSTransaction in Own Shares
24th Sep 20259:50 amRNSQuarterly Factsheet June 2025 & Newsletter H2 2025
24th Sep 20258:45 amRNSUpdate on Offer for Subscription
23rd Sep 20252:51 pmRNSQuarterly Factsheet June 2025 & Newsletter H2 2025
11th Sep 20255:08 pmRNSDirector/PDMR Shareholding
9th Sep 20255:59 pmRNSTransaction in Own Shares
4th Sep 20253:15 pmRNSNet Asset Value(s)
4th Sep 20258:15 amRNSIntention to Fundraise
6th Aug 20254:15 pmRNSNet Asset Value(s)
31st Jul 20257:00 amRNSTransaction in Own Shares
28th Jul 202510:00 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.